EICHOR

All briefs

Trial Enrollment Watch — July 27 – August 3, 2026

Overview

This week's scan of public ClinicalTrials.gov records identified 58 newly registered trials across major therapeutic areas, alongside 16 enrollment-distress indicators flagged by our heuristics and 113 previously completed trials added to our rolling index of the overdue-results backlog. Oncology and rare disease continue to dominate registration volume, with 21 new oncology trials and 22 new rare disease trials recorded this week.

Notable New Registrations

• NCT07728188 — AbbVie, Relapsed or Refractory Multiple Myeloma, Phase 3, 66 sites
• NCT07735637 — AstraZeneca, Newly Diagnosed Multiple Myeloma, Phase 3, 65 sites
• NCT07740564 — Ocumension Therapeutics, Dry Eye, Phase 3, 49 sites
• NCT07729462 — Pfizer, Preventive Treatment of Migraine, Phase 3, 2 sites
• NCT07727538 — Ionis Pharmaceuticals, Familial Chylomicronemia Syndrome, Phase 3, 1 site
• NCT07733765 — Pfizer, Alopecia Areata, Phase 3, 4 sites

The spread between large, multi-site pivotal studies (AbbVie, AstraZeneca) and single- or low-site registrations (Ionis, several Chinese sponsors) is a useful early read on how differently sponsors are approaching site network buildout for the same wave of Phase 3 starts.

Enrollment Distress Signals

Our heuristics flagged 16 enrollment-distress indicators this week, concentrated in rare disease (10) and oncology (4), with single flags each in cardiovascular and immunology. Rare disease trials continue to show the highest concentration of distress signals relative to new registrations in that same area, consistent with the smaller eligible-patient pools typical of the space.

Overdue Results Backlog

Separately, our rolling index — built against the FDA's March 2026 estimate of a 3,000+ trial standing backlog of completed studies with no results posted more than 12 months later — added 113 trials this week. Rare disease again accounts for the largest share, with 64 previously completed trials added, followed by oncology at 26. Infectious disease, neurology, and respiratory each contributed smaller additions (5, 5, and 4 respectively). This reflects the pace of our scan coverage against a large existing backlog, not new activity occurring this week.

Practical Takeaway

For site selection teams, the co-occurrence of high new-trial volume and elevated distress flags in rare disease warrants extra diligence: feasibility assessments should weight prior enrollment performance and site-level patient-finding capability more heavily than raw site counts, particularly for single- or dual-site Phase 3 designs entering a crowded competitive landscape.

Eichor generates free preliminary site-risk snapshots from public data for teams evaluating any of the trials above.

Clinical intelligence from public evidence

Use of Eichor is governed by our Terms of Use · Privacy Policy

© 2026 Biomedistats LLC (dba Eichor)